Savara Inc. (SVRA) SEC Filings & Earnings Calls

Regulatory delay risk

“The FDA determined that the Company’s responses to recent information requests by the Agency during their review constituted a major amendment to the BLA, resulting in a three-month extension of the Prescription Drug User Fee Act ("PDUFA") target action date to November 22, 2026.” · word for word

Capital need risk

“We will continue to require additional capital to continue our clinical development and potential commercialization activities.” · word for word

Key executive departure due to health reasons may indicate leadership instability, though transition appears orderly.

“CFO David Lowrance resigns due to health reasons; consulting agreement at $200/hour.”

Regulatory approval delay

“The FDA determined that the Company’s responses to recent information requests by the Agency during their review constituted a major amendment to the BLA, resulting in a three-month extension of the Prescription Drug User Fee Act ("PDUFA") date to November 22, 2026.” · word for word

Cash burn and need for additional capital

“We will continue to require additional capital to continue our clinical development and potential commercialization activities.” · word for word

Regulatory approval risk

“Marketing applications for MOLBREEVI for the treatment of autoimmune PAP are currently under review by regulatory authorities in the U.S., EU, and UK.” · word for word

Dilution risk from authorized share increase

“To approve an amendment to our Certificate of Incorporation to increase the number of authorized shares of our common stock from 300,000,000 to 600,000,000.” · word for word

Dilution risk from equity plan increase

“To approve the amendment of the Savara Inc. 2024 Omnibus Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder by 18,900,000.” · word for word

No product revenue; history of losses

“We have incurred operating losses and negative cash flow from operations and have no product revenue from inception to date.” · word for word

FDA Refusal to File delays BLA review

“In May 2025 we received the RTF requesting the Company provide additional data related to Chemistry, Manufacturing, and Controls.” · word for word

Significant operating losses and cash burn

“For the year ended December 31, 2025, we incurred a net loss of $118.8 million, and net cash used in operating activities was $101.0 million.” · word for word

Competitor Orphan Drug exclusivity risk

“If a competitor obtains Orphan Drug exclusivity for a product with the same active ingredient and route of delivery as molgramostim for autoimmune PAP, we may be unable to market our product candidate until the exclusivity of the competing product expires.” · word for word

Manufacturing supply chain concentration

“MOLBREEVI is currently manufactured entirely outside the U.S. and, as a result, we may experience interruptions in supply due to shipping or customs difficulties or regional instability.” · word for word

Debt covenant restrictions

“The Hercules Loan Agreement includes a number of restrictive covenants, including restrictions on incurring additional debt, making investments, granting liens, disposing of assets, paying dividends, and redeeming or repurchasing capital stock.” · word for word

Dependence on FDA approval for additional funding; loan secured by IP.

“Ability to draw $75M additional term loans subject to FDA approval of MOLBREEVI. Lenders granted first-priority perfected security interest in intellectual property.”

Pipeline dependency on MOLBREEVI regulatory approval

“Forward-looking statements highlight risks of clinical development, regulatory approval, and commercialization for MOLBREEVI.”

FDA Regulatory Delay

“In May 2025, Savara announced the Company had received a Refusal to File ("RTF") letter from the FDA.” · word for word

Government Shutdown Impact

“During this shutdown, the FDA is not accepting new drug applications, abbreviated new drug applications for generics, or BLA's.”

No Product Revenue

“We have incurred operating losses and negative cash flow from operations and have no product revenue from inception to date.” · word for word

Capital Need

“We will continue to require additional capital to continue our clinical development and potential commercialization activities.” · word for word

Significant dilution to existing shareholders from equity offering.

“23,809,524 shares plus 7,142,857 pre-funded warrants”

Potential further dilution if underwriters exercise option for additional 4.6M shares.

“option to purchase up to an additional 4,642,857 shares” · word for word

Royalty financing contingent on FDA approval by March 2027; no guarantee of approval.

“upon approval of the Company’s investigational inhaled biologic, molgramostim inhalation solution, for the treatment of autoimmune pulmonary alveolar proteinosis by the FDA on or before March 31, 2027” · word for word

Covenants limit incurrence of indebtedness until certain net sales achieved.

“covenants that limit or restrict the Company’s ability to, among other things, incur indebtedness (which restrictions are eliminated after the achievement by the Company of a specified amount of Net Sales)” · word for word